Application of computer to monitoring and control of fermentation process: Microbial conversion of ML‐236B Na to pravastatin

Biotechnology and Bioengineering
1993.0

Abstract

<jats:title>Abstract</jats:title><jats:p>An automatic feeding process for microbial hydroxylation of ML236B sodium salt (ML‐236B Na; compactin) by <jats:italic>Streptomyces carbophilus</jats:italic> SANK 62585 was developed. The hydroxylated product, pravastatin sodium salt (pravastatin; trade name Mevalotin), is an inhibitor of 3‐hydroxy‐3‐methyglutaryl–coenzyme A reductase (HMG–CoA reductase) used as cholesterol‐lowering drug. The hydroxylation activity of <jats:italic>S. carbophilus</jats:italic> was induced by the addition of ML236B Na to culture broth but inhibited by high concentration of ML236B Na. In order to obtain high conversion yield, it was necessary to maintain optimum ML236B Na concentration throughout the fermentation by continuous feeding. For this purpose, we developed an on‐line monitoring method, which mainly consisted of a cross‐flow filtration module, high‐performance liquid chromatography (HPLC) analyzer, feed pump, and microcomputer for regulation of ML236B Na concentration. An algorithm for control of ML236B Na feed rate based on feedback and feed‐forward control where conversion rate after Δ<jats:italic>t</jats:italic> was estimated by using regression analysis of the five latest values of conversion rate. In a fed‐batch culture employing this system, the concentration of ML236B Na was maintained at optimum level during the fermentation and the productivity of pravastatin was increased threefold over that obtained in manual control culture. © 1993 John Wiley &amp; Sons, Inc.

Knowledge Graph

Similar Paper

Application of computer to monitoring and control of fermentation process: Microbial conversion of ML‐236B Na to pravastatin
Biotechnology and Bioengineering 1993.0
Research and Development of Pravastatin
YAKUGAKU ZASSHI 1991.0
None
None nan
Tracing the Past Half Century of My Microbial Transformation Studies
YAKUGAKU ZASSHI 2000.0
Molecular approaches for production of pravastatin, a HMG-CoA reductase inhibitor: transcriptional regulation of the cytochrome P450sca gene from Streptomyces carbophilus by ML-236B sodium salt and phenobarbital
Gene 1998.0
A two component-type cytochrome P-450 monooxygenase system in a prokaryote that catalyzes hydroxylation of ML-236B to pravastatin, a tissue-selective inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase
Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism 1991.0
Strain Improvement of Streptomyces xanthochromogenes RIA 1098 for Enhanced Pravastatin Production at High Compactin Concentrations
Indian Journal of Microbiology 2015.0
Cloning, characterization and expression of the gene encoding cytochrome P-450sca-in2 from Streptomyces carbophilus involved in production of pravastatin, a specific HMG-CoA reductase inhibitor
Gene 1995.0
Mass production of thiostrepton by fed-batch culture of Streptomyces laurentii with pH-stat modal feeding of multi-substrate
Applied Microbiology and Biotechnology 1987.0
Eurystatins A and B, new prolyl endopeptidase inhibitors. III. Fermentation and controlled biosynthesis of eurystatin analogs by Streptomyces eurythermus.
The Journal of Antibiotics 1994.0